PLANNED MAINTENANCE

There will be scheduled maintenance work beginning on Wednesday 26th February 2020 from 11:00 AM through to 12.00 PM (GMT).

During this time, you may not be able to log into ChemSpider. We apologise for any inconvenience this might cause and thank you for your patience.

ChemSpider 2D Image | Ravoxertinib | C21H18ClFN6O2

Ravoxertinib

  • Molecular FormulaC21H18ClFN6O2
  • Average mass440.858 Da
  • Monoisotopic mass440.116394 Da
  • ChemSpider ID32501977

  • defined stereocentres - 1 of 1 defined stereocentres

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1-[(1S)-1-(4-Chlor-3-fluorphenyl)-2-hydroxyethyl]-4-{2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl}-2(1H)-pyridinon [German] [ACD/IUPAC Name]
1-[(1S)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl]-4-{2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl}-2(1H)-pyridinone [ACD/IUPAC Name]
1-[(1S)-1-(4-Chloro-3-fluorophényl)-2-hydroxyéthyl]-4-{2-[(1-méthyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl}-2(1H)-pyridinone [French] [ACD/IUPAC Name]
10386
1453848-26-4 [RN]
2(1H)-Pyridinone, 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]- [ACD/Index Name]
R6AXV96CRH
ravoxertinib [French] [INN]
ravoxertinib [Spanish] [INN]
Ravoxertinib [INN] [USAN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

GDC0994 [DBID]
GDC-0994 [DBID]
RG-7842 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      ERK MedChem Express HY-15947
      GDC-0994 is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively. MedChem Express
      GDC-0994 is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.; IC50 value: 1.1 nM/0.3 nM(ERK1/ERK2) [1]; Target: ERK1/ERK2 inhibitor; Daily, oral dosing of GDC-0994 results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. MedChem Express HY-15947
      GDC-0994 is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.;IC50 value: 1.1 nM/0.3 nM(ERK1/ERK2) [1];Target: ERK1/ERK2 inhibitorDaily, oral dosing of GDC-0994 results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. PD biomarker inhibition of phospho-p90RSK in these tumors correlates with potency in vitro and in vivo. In contrast to other published ERK inhibitors, GDC-0994 neither increases nor decreases phospho-ERK, suggesting that different ERK inhibitors have alternative mechanisms of action with respect to feedback signaling. Furthermore, we demonstrate a novel approach for targeting the oncogenic signaling through the RAS pathway by combining ERK and MEK inhibitors. GDC-0994 is currently in Phase I clinical development. MedChem Express HY-15947
      MAPK MedChem Express HY-15947
      MAPK; MedChem Express HY-15947

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density: 1.5±0.1 g/cm3
Boiling Point: 734.6±70.0 °C at 760 mmHg
Vapour Pressure: 0.0±2.5 mmHg at 25°C
Enthalpy of Vaporization: 112.5±3.0 kJ/mol
Flash Point: 398.0±35.7 °C
Index of Refraction: 1.687
Molar Refractivity: 115.3±0.5 cm3
#H bond acceptors: 8
#H bond donors: 2
#Freely Rotating Bonds: 6
#Rule of 5 Violations: 0
ACD/LogP: 2.18
ACD/LogD (pH 5.5): 2.03
ACD/BCF (pH 5.5): 20.50
ACD/KOC (pH 5.5): 301.63
ACD/LogD (pH 7.4): 2.03
ACD/BCF (pH 7.4): 20.69
ACD/KOC (pH 7.4): 304.42
Polar Surface Area: 96 Å2
Polarizability: 45.7±0.5 10-24cm3
Surface Tension: 55.5±7.0 dyne/cm
Molar Volume: 302.7±7.0 cm3

Click to predict properties on the Chemicalize site


Advertisement